Regeneron Pharmaceuticals (REGN) Change in Accured Expenses (2009 - 2026)

Regeneron Pharmaceuticals has reported Change in Accured Expenses for 18 years, with the latest figure at $492.7 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 127.68% year-over-year to $492.7 million in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 216.1% increase from a year earlier, with the FY2025 full-year figure at $736.8 million, changed 0.23% from the prior year.
• Change in Accured Expenses was $492.7 million for Q2 2026 at Regeneron Pharmaceuticals, up from $107.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $759.2 million in Q3 2025, with the low at -$250.4 million in Q1 2022.
• Average Change in Accured Expenses over 5 years is $140.7 million, with a median of $114.8 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 621.61% in 2022, then jumped 460.95% in 2023.
• Over 5 years, Change in Accured Expenses stood at $347.6 million in 2022, then slumped by 139.9% to -$138.7 million in 2023, then soared by 262.65% to $225.6 million in 2024, then tumbled by 110.95% to -$24.7 million in 2025, then soared by 2094.74% to $492.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $492.7 million (Q2 2026), $107.7 million (Q1 2026), and -$24.7 million (Q4 2025), per Business Quant data.